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S202Acute type B aortic dissection (identified within 2 weeks of symptom onset), as described using the Stanford
classification, involves the aorta distal to the left subclavian artery and accounts for 25%-40% of all aortic dis-
sections. The traditional treatment paradigm of medical management for uncomplicated acute type B dissection
and open surgical intervention for early or late complications of type B dissection is currently undergoing a pe-
riod of evolution as a result of the influence of minimally invasive thoracic endovascular aortic repair options.
Thoracic endovascular repair has replaced open surgical repair as the preferred treatment for complicated acute
type B dissection, andmay also prove beneficial for prophylactic repair of uncomplicated acute type B dissection
for high-risk patients. This review discusses the management of acute type B aortic dissection and long-term
treatment considerations. (J Thorac Cardiovasc Surg 2013;145:S202-7)Acute type B dissections may be classified as uncompli-
cated or complicated, with complicated disease generally
referring to the presence of rupture or impending rupture,
malperfusion, and/or refractory pain or hypertension.1
Complicated dissections, which represent 15% to 20%
of cases, require surgical or interventional therapy, and
Thoracic endovascular aortic repair (TEVAR) has gener-
ally replaced open surgery or fenestration as the treatment
of choice for this clinical problem.
For patients with dynamic malperfusion caused by
branch vessel occlusion of the true lumen by the pressur-
ized false lumen (Figure 12,3), endovascular treatment
aims to restore antegrade flow within the true lumen and re-
duce false lumen flow by stent graft coverage of the pri-
mary tear. Additional distal bare-metal stenting of the
visceral segment and/or iliacs may be required to reexpand
the distal true lumen, and femoral–femoral bypass may be
required for long-segment unilateral iliac occlusion
(Figure 2). For patients with static malperfusion caused
by propagation of the dissection into branch vessel ostia
with distal vessel occlusion (Figure 1), coverage of the pri-
mary tear and restoration of true lumen flow alone gener-
ally does not relieve the malperfusion syndrome, and thus
endovascular treatment also requires branch vessel stenting
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The Journal of Thoracic and Cardiovascular Surif endovascular attempts are unsuccessful.2 Regardless of
the management approach, this form of malperfusion is as-
sociated with significant mortality, especially if the static
malperfusion process involves the visceral vessels.4 For pa-
tients with contained or frank rupture (Figure 4), endovas-
cular repair is more complex and requires sealing off the
primary tear as well as the site of the leak, and frequently
necessitates paving the entire thoracic aorta when the site
of the leak is unclear.
Intravascular ultrasound and transesophageal echocardi-
ography are superior to angiography for identifying pri-
mary and distal reentry tears, documenting guidewire
position in the true lumen, assessing seal zones, and detect-
ing endoleaks,5 and are used for all TEVAR dissection
cases at our institution (Figure 5). We also consider intra-
vascular ultrasound and transesophageal echocardiography
assessment of the ascending aorta to be mandatory at the
conclusion of each TEVAR case to assess for retrograde as-
cending aortic dissection, a catastrophic complication of
TEVAR that occurs more frequently when treating dissec-
tion (Figure 5).6,7 Thoracic endovascular aortic repair is
generally avoided in patients with connective tissue
disease because of a high rate of treatment failure;
however, endovascular therapy may provide a successful
bridge to open treatment in select patients with
connective tissue disease with complicated acute type B
dissection, provided careful follow-up at an experienced
aortic center is ensured.8,9
Observational data comparing endovascular therapy
with open repair of acute complicated type B dissection
favor overwhelmingly the endovascular approach. For
example, the International Registry of Acute Aortic Dis-
section (IRAD) reported an in-hospital death rate of
33% for patients with acute complicated type B dissec-
tion treated by open surgery, compared with 11% for
patients treated by endovascular therapy.10 A meta-
analysis of 29 studies reporting outcomes after endovas-
cular repair of acute complicated type B dissection
further reported an in-hospital mortality rate of 9%.11
The use of TEVAR for complicated dissection remainsgery c March 2013
Hughes et al Panel 4FIG
wit
rest
fus
rest
ma
distAbbreviations and Acronyms
IRAD ¼ International Registry of Acute
Aortic Dissection
TEVAR ¼ thoracic endovascular aortic repairURE 1
h chang
oration
ion resu
oration
lperfusi
ally wi. Malperf
es in the c
of antegra
lts from ex
of antegra
on of the s
thin the SMinvestigational in the United States, although clinical trials
to gain U.S. Food and Drug Administration approval are
complete or nearly complete. Nonetheless, consensus state-
ments from the Society of Thoracic Surgeons and the Amer-
ican Heart Association have already supported the use of
TEVAR for acute complicated type B dissection.1,12UNCOMPLICATED ACUTE TYPE B DISSECTION
Medical management with anti-impulse therapy has
remained the preferred treatment option for uncomplicated
acute type B dissection, with in-hospital mortality ratesusion syndromes. A, Dynamic malperfusion results in bran
ardiac cycle as well as with variations in pressure in the
de true lumen flow. B, Computed tomographic angiogram
tension of the dissection process into the branch vessel with
de true lumen flow and requires branch vessel stenting or s
uperior mesenteric artery (SMA). Note that the dissection
A.2,3 F ¼ False lumen; T ¼ true lumen. Reprinted with
The Journal of Thoracic and Cardtypically <10% with this strategy.13-15 Although
interventional therapies may struggle to improve on
medical management in the acute setting, when one
examines longer term follow-up data, the results of medical
management are less satisfactory. Data from IRAD reveal
3-year survival of medically managed patients discharged
alive after hospitalization for acute type B dissection to be
only 78%.16 Admittedly, a significant proportion of the late
mortality is the result of patient comorbid conditions, but nu-
merous studies have demonstrated that 25% to 50% of med-
ically treated patients develop late aortic-related
complications, most commonly aneurysmal degeneration
of the false lumen.1 The upper thoracic aorta appears to be
the major site of aneurysmal degeneration, with patency of
the false lumen being the major risk factor for a late increase
in aortic size.17
Given that numerous reports have found that a throm-
bosed false lumen predicts lower event rates after type B
dissection,18 many have speculated that prophylactic
TEVAR for uncomplicated type B dissection may promotech vessel obstruction by the intimal flap. The degree of obstruction can vary
false lumen. This type of malperfusion syndrome is generally relieved via
demonstrating dynamic malperfusion of the celiac axis. C, Static malper-
subsequent distal occlusion. This malperfusion syndrome is not relieved by
urgical bypass. D, Computed tomographic angiogram demonstrating static
extends out into the SMA and that both true and false lumens are occluded
permission from Elsevier.
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FIGURE 4. Acute type B dissection complicated by contained rupture
into the left hemithorax.
FIGURE 2. Computed tomographic angiography with 3-dimensional ren-
dering demonstrating proximal thoracic endovascular aortic repair
(TEVAR) with distal aorto-uni-iliac device placement and femoral–femoral
(fem-fem) bypass for a patient with complicated acute type B dissection
with long-segment unilateral iliac occlusion. EVAR, Endovascular aortic
repair.
FIGURE 3. Subtraction angiography demonstrating bare-metal stent-
ing of the superior mesenteric artery (SMA) with restoration of distal
flow in a patient (computed tomographic scan shown in Figure 1, D)
with acute complicated type B dissection with static SMA malperfu-
sion.
Panel 4 Hughes et alfalse lumen thrombosis and prevent late aneurysm forma-
tion. The Investigation of Stent Grafts in Aortic Dissection
trial attempted to study this question. The trial randomized
low-risk, subacute (2-52 weeks from symptom onset) type
B dissection patients to TEVAR or optimal medical man-
agement and found no difference in the primary end point
of all-cause mortality at 2 years.19 Patients randomized to
TEVAR did have significantly greater aortic remodeling,
defined as true lumen recovery with thoracic false lumen
thrombosis, which occurred in 91.3% of TEVAR patients
versus only 19.4% of medically managed patients
(P< .001). However, this did not translate into improved
aorta-related survival, mainly because of a high rate of
aorta-related deaths in the TEVAR group resulting from
periprocedural technical complications. These complica-
tions, which included access vessel rupture, retrograde
type A dissection, and thoracic aortic rupture despite
TEVAR, were likely related to the short length of aortic
pavement (<15 cm in most patients) and the use of an ear-
lier generation thoracic device suboptimal for this applica-
tion. The complication rate observed was much higher
than would be considered acceptable in more recent series
using devices better suited to this application.20 Further-
more, the trial had other limitations and does notS204 The Journal of Thoracic and Cardiovascular Surrepresent the final word on this subject. Most notably,
only patients who survived 2 weeks after symptom onset
without intervention were included in the trial, potentially
excluding high-risk patients who would be expected to de-
rive the greatest benefit from early intervention. Last, al-
though the results of medical management were goodgery c March 2013
FIGURE 5. A, Intravascular ultrasound (IVUS) demonstrating true and false lumens and confirming true lumen guidewire access. B, Transesophageal
echocardiography assessment of the proximal aorta at case completion demonstrating new retrograde type A dissection.
Hughes et al Panel 4for these low-risk patients, two thirds of the deaths in the
medical management group were secondary to aortic
rupture.
A number of studies have suggested several subsets of
high risk uncomplicated patients who may benefit
from early TEVAR. Specific predictors of early or late
adverse events identified in multiple studies include an
initial aortic diameter 4.0 cm with a patent false
lumen,15,21,22 an initial false lumen diameter 22 mm
in the proximal descending aorta,23 recurrent/refractory
pain or hypertension,24 or intramural hematoma with de-
velopment of a penetrating atherosclerotic ulcer in the
proximal descending aorta15,22 (Table 1). However, un-
certainty remains regarding the optimal management
strategy for high-risk uncomplicated acute type B dis-
section, and the final answer to this question awaits
a well-designed, prospective, randomized controlled
trial.LONG-TERM MANAGEMENT
Long-term mortality after hospital discharge is greater
for type B dissection than for type A dissection, and atten-
tive medical management and aortic surveillance are re-
quired. Specific predictors of follow-up mortality include
female gender, prior aortic aneurysm, atherosclerosis,
pleural effusion, and in-hospital acute renal failure,
hypotension, or shock.16 Medical management withTABLE 1. High-risk features of uncomplicated type B dissection
Clinical feature References
Initial aortic diameter 4.0 cm with patent false lumen 15, 21, 22
Initial false lumen diameter 22 mm in proximal DTA 23
IMH with PAU in proximal DTA 15, 22
Recurrent/refractory pain or hypertension 24
DTA, Descending thoracic aorta; IMH, intramural hematoma; PAU, penetrating ath-
erosclerotic ulcer.
The Journal of Thoracic and Cardb-blockade and blood pressure control remains the corner-
stone of long-term therapy for type B dissection25;
however, a recent report from IRAD also found that the
use of calcium channel blockers at discharge was associ-
ated with improved long-term survival selectively in
medically treated type B dissection patients.26 The mech-
anism of this mortality benefit was unclear, and the au-
thors speculated that the findings may be the result of
differences in the typically more elderly type B patient
population as well as potential selective effects of
calcium channel blockers on descending aortic remodel-
ing. Regardless, the authors consider the results prelimi-
nary and hypothesis generating, and stress the need for
randomized controlled trials to define more completely
optimal medical management in this population.26
Despite optimal medical management, at least one third
of patients will require surgery for aortic-related compli-
cations within 5 years of the initial dissection, and the
risk is most substantial within the first few months. Serial
imaging at 1, 3, 6, and 12 months after discharge, and an-
nually thereafter, is therefore recommended to allow for
timely recognition and surgical repair of late problems
of type B dissection, most commonly aneurysmal degen-
eration of a patent false lumen.25CONCLUSIONS
Treatment options for type B aortic dissection are
evolving in the endovascular era. Medical management
remains the preferred strategy for uncomplicated acute
type B dissection, and medical compliance is critical
(Figure 6). There remains little or no debate in the liter-
ature regarding the preferred choice of TEVAR for
acute complicated type B dissection, but the potential
role for TEVAR for high-risk uncomplicated type B
dissection requires additional study. Close lifelong aortic
surveillance to identify and repair problems of chronic
dissection is mandatory for all patients.iovascular Surgery c Volume 145, Number 3S S205
FIGURE 6. A case of type B dissection with rapid aneurysmal dilation resulting from medical noncompliance. A-C, A 30-year-old male with a history of
malignant hypertension presented with an uncomplicated acute type B dissection with no high-risk anatomic features and was treated by medical manage-
ment. D-F, At the 1-month follow-up visit, aortic diameters were stable but the patient’s blood pressure was poorly controlled. G and H, The patient missed
all subsequent follow-up appointments and re-presented 16 months later with hypertensive urgency resulting from medical noncompliance. The maximal
aortic diameter was found to have enlarged by 2 cm over the 16-month interval and was treated successfully by open extent 1 thoracoabdominal aortic
aneurysm (TAAA) repair.
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